Zhi Q X, Yi F H, XI C T
Department of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, People's Republic of China.
Neuroreport. 1995 Nov 13;6(16):2221-4.
Huperzine A, a novel, potent, reversible, and selective acetylcholinesterase (AChE) inhibitor has been expected to be superior to other AChE inhibitors now for the treatment of memory deficits in patients with Alzheimer's disease. We have assessed the effects of huperzine A on performance of AF64A-treated rats in the radial maze. AF64A (2 nmol per side, i.c.v.) caused significant impairment in rats' ability to perform the spatial working memory task. This behavioural impairment was associated with a significant decrease in the activity of choline acetyltransferase (ChAT) in the hippocampus. Huperzine A (0.4-0.5 mg kg-1, i.p.) significantly ameliorated the AF64A-induced memory deficit. These results suggest that AF64A is a useful agent for disrupting working memory processes by altering hippocampal cholinergic function, and such impairment can be effectively ameliorated by huperzine A.
石杉碱甲是一种新型、强效、可逆且具有选择性的乙酰胆碱酯酶（AChE）抑制剂，目前有望在治疗阿尔茨海默病患者的记忆缺陷方面优于其他AChE抑制剂。我们评估了石杉碱甲对经AF64A处理的大鼠在放射状迷宫中行为表现的影响。AF64A（每侧2纳摩尔，脑室内注射）显著损害了大鼠执行空间工作记忆任务的能力。这种行为损伤与海马体中胆碱乙酰转移酶（ChAT）的活性显著降低有关。石杉碱甲（0.4 - 0.5毫克/千克，腹腔注射）显著改善了AF64A诱导的记忆缺陷。这些结果表明，AF64A是一种通过改变海马体胆碱能功能来破坏工作记忆过程的有效药物，而这种损伤可以被石杉碱甲有效改善。
